[HTML][HTML] EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong–A cost-effectiveness analysis
Introduction Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth factor
receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …
receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong-A cost-effectiveness analysis
JHS You, WCS Cho, W Ming, Y Li, C Kwan, K Au… - PLOS …, 2021 - scholars.cityu.edu.hk
Abstract Introduction Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth
factor receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …
factor receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …
[PDF][PDF] EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong A cost-effectiveness analysis
JHS You, WCS Cho, LY Ming Wk, AK Kwan Ck - PLoS ONE, 2021 - academia.edu
Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth factor receptor (EGFR)
gene mutations in non-small-cell lung cancer (NSCLC). We aimed to compare the EGFR …
gene mutations in non-small-cell lung cancer (NSCLC). We aimed to compare the EGFR …
[PDF][PDF] EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong A cost-effectiveness analysis
JHS You, WCS Cho, LY Ming Wk… - PLoS …, 2021 - pdfs.semanticscholar.org
Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth factor receptor (EGFR)
gene mutations in non-small-cell lung cancer (NSCLC). We aimed to compare the EGFR …
gene mutations in non-small-cell lung cancer (NSCLC). We aimed to compare the EGFR …
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong-A cost-effectiveness analysis.
JHS You, WCS Cho, WK Ming, YC Li, CK Kwan, KH Au… - Plos one, 2021 - europepmc.org
Methods A Markov model was designed to simulate outcomes of a hypothetical cohort of
advanced (stage IIIB/IV) NSCLC adult patients with un-tested EGFR-sensitizing mutation …
advanced (stage IIIB/IV) NSCLC adult patients with un-tested EGFR-sensitizing mutation …
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong–A cost-effectiveness analysis.
JHS You, W Cho, W Ming, Y Li, C Kwan, K Au… - PLoS …, 2021 - search.ebscohost.com
Abstract Introduction: Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth
factor receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …
factor receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …
[引用][C] EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong–A cost-effectiveness analysis
JHS You, W Cho, W Ming, Y Li, C Kwan, K Au… - PLoS …, 2021 - ui.adsabs.harvard.edu
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung
cancer in Hong Kong – A cost-effectiveness analysis - NASA/ADS Now on home page ads …
cancer in Hong Kong – A cost-effectiveness analysis - NASA/ADS Now on home page ads …
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong-A cost-effectiveness analysis
JHS You, WCS Cho, WK Ming, YC Li, CK Kwan… - PloS …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth factor
receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …
receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …
[HTML][HTML] EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong–A cost-effectiveness analysis
JHS You, WCS Cho, W Ming, Y Li, C Kwan, K Au… - PLoS ONE, 2021 - ncbi.nlm.nih.gov
Methods A Markov model was designed to simulate outcomes of a hypothetical cohort of
advanced (stage IIIB/IV) NSCLC adult patients with un-tested EGFR-sensitizing mutation …
advanced (stage IIIB/IV) NSCLC adult patients with un-tested EGFR-sensitizing mutation …
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong–A cost-effectiveness analysis
JHS You, WCS Cho, W Ming, Y Li, C Kwan, K Au… - PLOS ONE, 2021 - ideas.repec.org
Introduction: Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth factor
receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …
receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …